Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Catalyst Pharmaceuticals (CPRX) Revenue (2018 - 2025)

Historic Revenue for Catalyst Pharmaceuticals (CPRX) over the last 11 years, with Q3 2025 value amounting to $148.4 million.

  • Catalyst Pharmaceuticals' Revenue rose 1530.52% to $148.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $578.2 million, marking a year-over-year increase of 2556.32%. This contributed to the annual value of $491.7 million for FY2024, which is 2348.8% up from last year.
  • Latest data reveals that Catalyst Pharmaceuticals reported Revenue of $148.4 million as of Q3 2025, which was up 1530.52% from $146.6 million recorded in Q2 2025.
  • Catalyst Pharmaceuticals' Revenue's 5-year high stood at $148.4 million during Q3 2025, with a 5-year trough of $30.2 million in Q1 2021.
  • Over the past 5 years, Catalyst Pharmaceuticals' median Revenue value was $98.5 million (recorded in 2024), while the average stood at $88.5 million.
  • As far as peak fluctuations go, Catalyst Pharmaceuticals' Revenue soared by 366.54% in 2021, and later surged by 9811.55% in 2023.
  • Over the past 5 years, Catalyst Pharmaceuticals' Revenue (Quarter) stood at $38.3 million in 2021, then skyrocketed by 58.6% to $60.8 million in 2022, then soared by 81.98% to $110.6 million in 2023, then rose by 28.26% to $141.8 million in 2024, then rose by 4.63% to $148.4 million in 2025.
  • Its last three reported values are $148.4 million in Q3 2025, $146.6 million for Q2 2025, and $141.4 million during Q1 2025.